Global Cord Blood (CO) Competitors $0.55 0.00 (0.00%) As of 08/14/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock CO vs. CORBF, MRAI, ABUS, GHRS, SIGA, BBNX, AXGN, CDNA, MGTX, and SBTXShould you be buying Global Cord Blood stock or one of its competitors? The main competitors of Global Cord Blood include Global Cord Blood (CORBF), Marpai (MRAI), Arbutus Biopharma (ABUS), GH Research (GHRS), Siga Technologies (SIGA), Beta Bionics (BBNX), AxoGen (AXGN), CareDx (CDNA), MeiraGTx (MGTX), and Silverback Therapeutics (SBTX). Global Cord Blood vs. Its Competitors Global Cord Blood Marpai Arbutus Biopharma GH Research Siga Technologies Beta Bionics AxoGen CareDx MeiraGTx Silverback Therapeutics Global Cord Blood (NYSE:CORBF) and Global Cord Blood (NYSE:CO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Is CORBF or CO more profitable? Company Net Margins Return on Equity Return on Assets Global Cord BloodN/A N/A N/A Global Cord Blood N/A N/A N/A Which has more risk and volatility, CORBF or CO? Global Cord Blood has a beta of -0.6, suggesting that its share price is 160% less volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Which has better earnings and valuation, CORBF or CO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlobal Cord Blood$196.12M0.34$79.04MN/AN/AGlobal Cord Blood$1.24B0.05$79.04M$0.640.86 Does the media favor CORBF or CO? In the previous week, Global Cord Blood and Global Cord Blood both had 1 articles in the media. Global Cord Blood's average media sentiment score of 0.67 beat Global Cord Blood's score of 0.00 indicating that Global Cord Blood is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Global Cord Blood 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Global Cord Blood 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGlobal Cord Blood beats Global Cord Blood on 3 of the 4 factors compared between the two stocks. Get Global Cord Blood News Delivered to You Automatically Sign up to receive the latest news and ratings for CO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CO vs. The Competition Export to ExcelMetricGlobal Cord Bloodhealth & allied services, not elsewhere classified IndustryMedical SectorNYSE ExchangeMarket Cap$66.85M$52.86M$5.67B$20.95BDividend YieldN/AN/A3.79%3.59%P/E Ratio0.860.4330.5827.94Price / Sales0.050.37463.4955.77Price / Cash4.192.8037.4023.77Price / Book0.090.099.095.26Net Income$79.04M$43.11M$3.25B$994.11M7 Day PerformanceN/A-37.02%7.42%1.79%1 Month Performance-26.67%-16.33%5.49%1.73%1 Year Performance-68.57%8.23%30.67%13.35% Global Cord Blood Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGlobal Cord BloodN/A$0.55flatN/A-68.6%$66.85M$1.24B0.861,202CORBFGlobal Cord BloodN/A$1.35flatN/A-68.6%$164.09M$196.12M0.001,200News CoverageMRAIMarpaiN/A$1.33-0.7%N/A+187.9%$22.17M$34.87M-0.50150News CoverageABUSArbutus Biopharma2.6014 of 5 stars$3.35-1.5%$5.50+64.2%-10.1%$651.78M$6.17M-11.5590News CoverageAnalyst RevisionGHRSGH Research3.0296 of 5 stars$11.80-4.9%$32.00+171.2%+29.2%$645.67MN/A-15.9510News CoveragePositive NewsAnalyst RevisionSIGASiga Technologies2.1112 of 5 stars$9.48+5.8%N/A-11.6%$641.59M$138.72M8.3940High Trading VolumeBBNXBeta Bionics2.6605 of 5 stars$14.30-3.0%$22.56+57.7%N/A$640.75M$65.12M0.00294AXGNAxoGen2.8933 of 5 stars$14.01+0.8%$26.00+85.6%+35.5%$639.58M$187.34M-140.09450Short Interest ↑CDNACareDx4.2944 of 5 stars$11.77-1.7%$27.67+135.1%-58.2%$637.13M$333.79M11.54740MGTXMeiraGTx4.4838 of 5 stars$7.84-0.5%$24.00+206.1%+85.7%$633.28M$33.28M-3.38300News CoverageEarnings ReportAnalyst ForecastSBTXSilverback TherapeuticsN/A$17.50-0.8%N/A+6.9%$631.02MN/A-7.2383High Trading Volume Related Companies and Tools Related Companies CORBF Competitors MRAI Competitors ABUS Competitors GHRS Competitors SIGA Competitors BBNX Competitors AXGN Competitors CDNA Competitors MGTX Competitors SBTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CO) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global Cord Blood Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Global Cord Blood With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access